Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer

(MedPage Today) -- Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial.
Estimated overall survival (OS) at...